Company intelligence / Profile preview

Chengdu JOYO

Chengdu, Sichuan Sheng, Chinajoy-motion.com ↗

Ownership: Private
Development stage: Other

Overview

Chengdu JOYO, officially known as Chengdu Youluo Biotechnology Co., Ltd., is a private Chinese biotech company focused on developing monoclonal antibody and nanobody therapeutics targeting cancer and nervous system diseases. Its lead program, EP‑9001A targeting NGF for cancer pain, has reached Phase 2 clinical trials as of May 2025. The company also has additional assets in discovery and preclinical stages but limited public clinical results are available.

Therapeutic areas: OncologyNeurology
Modalities: Monoclonal antibodiesNanobodies
Industry: Biotech

Beyond the preview

Go deeper on Chengdu JOYO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu JOYO.

Explore the full profile